Skip to main content

Aldaver

ApplicationT335, 336, 341 Truth hall, 193, Munji-ro, Yuseong-gu, Daejeon, Republic of Korea (KAIST, Munji Campus)Founded 2022· One of 702 Application companies tracked by AMPulse

A medical technology startup developing hyper-realistic, biopolymer-based artificial organ simulators designed for high-fidelity surgical training and medical device validation.

CEO / Founder
Kim Jin-oh, Steve Park
Team Size
11-50
Stage
Active
Total Funding
$9.6M
Latest Round
Series A
Key Investors
SL Investment, Korea Investment Partners, Daily Partners, KB Investment, Ascendo Ventures, Bluepoint Partners

Technology & Products

Key Products

Biopolymer + 3D-printed artificial organ simulators for surgical training and device validation: BPH Treatment Simulator (Compact), TURBT, Kidney RIRS, Partial Nephrectomy, Prostatectomy, plus laparoscopy line expansion (2025). Online store at aldaver.co.kr/shop.

Technical position · AMPulse analysis

Leverages the founder's expertise in 'electronic skin' and flexible electronics to integrate sensory feedback into simulators, bridging the gap between static plastic models and living tissue.

Patent position

Aldaver filed 15 patent families across all years. AMPulse analysis

Filing momentum
15 families filed 2022–2024, 0 in 2019–2021
Filed in
KR 53%WO 27%EP 13%US 7%

15 AM patent families in total. Recent years are still being published, so read a filing change against the same-office figure.

Differentiation

Value Proposition

Provides a high-fidelity, ethical alternative to animal testing and human cadavers by mimicking the exact mechanical resistance and electrical conductivity of living human tissue.

How They Differentiate

Aldaver differentiates through its proprietary 'Liquid-to-Solid' biopolymer technology and 'electronic skin' expertise. Unlike traditional plastic models, Aldaver’s simulators mimic the exact electrical conductivity and mechanical resistance of living tissue, allowing for the realistic use of electrosurgical and robotic tools that typically fail on standard synthetic materials.

Market & Competition

Target Customers

Medical schools, teaching hospitals, surgical training centers, and global medical device manufacturers (R&D and sales divisions).

Industry Verticals

Medical Technology (MedTech), Healthcare Education, Surgical Robotics, Medical Device Manufacturing

Competitors

CAE Healthcare, IngMar Medical, SynDaver Labs

Growth & Milestones

Growth Metrics

Homepage metrics: 20 models, 160 partnering companies, 6,000 users; ~46–47 employees (THE VC / 국민연금 mid-2026); 4.4x valuation step-up Pre-A→Series A; dedicated manufacturing at Osong High-Tech Medical Complex; active global exhibition calendar through 2026.

Major Milestones

Recipient of the CES 2023 Innovation Award for realistic medical simulators, Successfully developed 'Liquid-to-Solid' biopolymer technology for haptic organ mimicry, Completed $8.4M Series A funding round in January 2025, Established specialized production line at Osong High-Tech Medical Complex

Notable Customers

Medical schools, teaching hospitals, surgical training centers, and global MedTech manufacturers (R&D/sales). Named activity with Teleflex (UroLift training); collaborations with VRiMS and Società Italiana di Andrologia (SIA); 160 partnering companies / 6,000 users claimed on site.

https://aldaver.co.kr

AM patents

AM-relevant patents linked to this company.

Patents
15
Granted
5
Families
15

Leading domains: process (15), application (14), equipment (3)

Filings by year: 2024: 3 · 2023: 7 · 2022: 5

  1. HYDROGEL COMPOSITION FOR 3D PRINTING, AND 3D PRINTING HYDROGEL PREPARED THEREFROM04644440 · EP
  2. 하이드로겔 조성물 및 이를 이용한 과립형 하이드로겔의 제조방법1020240145982 · KR
  3. 3D 프린팅 인공 조직 형성용 조성물 및 이를 이용한 인공 조직의 제조방법1029198140000 · KR
  4. BIG DATA-BASED ARTIFICIAL ORGAN PRODUCTION SYSTEM20260199095 · US
  5. 3D 프린팅 잉크 조성물 및 이를 경화하여 형성되는 3D 프린팅 성형품1020240141707 · KR

Funding rounds

  • Series A$7.7M2024-12Lead: SL Investment · Source: KoreaTechDesk
  • Pre-Series A$1.9M2022-09Lead: Bluepoint Partners · Source: Web

Why this company matters

AMPulse analysis, not a company disclosure

Aldaver produces hyper-realistic, biopolymer-based artificial organ simulators designed to replace animal testing and human cadavers in surgical training and medical device validation. Its proprietary 'Liquid-to-Solid' biopolymer technology creates synthetic tissues that replicate the haptic feedback and electrical conductivity of living human tissue, enabling realistic use of electrosurgical and robotic tools that fail on standard plastic models.

The company's simulators target urological and vascular procedures, skin, and benign prostatic hyperplasia (BPH). Customers include medical schools, teaching hospitals, surgical training centers, and global medical device manufacturers. Aldaver has collaborated with VRiMS and the Società Italiana di Andrologia (SIA), and works with Asan Medical Center for clinical validation.

Founded in 2021 and based at KAIST's Munji Campus in Daejeon, Aldaver leverages the founder's expertise in electronic skin and flexible electronics to integrate sensory feedback into its simulators. The company holds nine registered patents in the medical or veterinary science category. It raised an $8.4 million Series A in January 2025, bringing total funding to $9.6 million, with investors including SL Investment, Korea Investment Partners, and KB Investment.

Aldaver differentiates from competitors like CAE Healthcare, IngMar Medical, and SynDaver Labs through its focus on electrical conductivity and mechanical resistance matching. Its simulators allow electrosurgical tool testing that other synthetic materials cannot support. The company has established a dedicated manufacturing facility at the Osong High-Tech Medical Complex and received a CES 2023 Innovation Award.